Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer
Crossref DOI link: https://doi.org/10.1007/s00280-014-2652-0
Published Online: 2014-12-27
Published Print: 2015-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Borin, Marie T.
Chen, Meng
Mocci, Simonetta
Rubets, Igor
Chittenden, Jason
Aldairy, Wassim
Stroh, Mark
Text and Data Mining valid from 2014-12-27